tbuckley/cabot-search huggingface dataset:
PWE-106 Colorectal Cancer: Experience of A District General Hospital in UK
Authors: I Papamargaritis, P Piskilidis, K Yoong
Journal: Gut (2016)

<h3>Introduction</h3> Colorectal cancer is a significant cause of morbidity and mortality in the UK with 40,000 new cases each year. The purpose of this study is to present the descriptive epidemiology of colorectal cancer in a district general hospital setting (Leighton Hospital – catchment area of 300,000 people). <h3>Methods</h3> All patients referred to the hospital between 01/01/12-31/12/13 were included.Data were obtained from case notes and computer based data: Date of referral Route of referral Diagnosis Treatment and recurrence Literature search via Medline. Statistical analysis by SPSS statistical package <h3>Results</h3> Demographics 380 patients (155 female(40.8%) and 225 (59.2%) male). Anatomical Site 11.3% had cancer in Caecum, 6.3% in Ascending Colon, 2.6% in Hepatic Flexure, 4.8% in Transverse Colon, 1.6% in Splenic Flexure, 4.8% in Descending Colon, 26.8% in Sigmoid, 32.1% in Rectum, 2.6% in Anus and 7.1% in other anatomical sites e.g appendix Type of Referral 42.3% of patients were referred by GP, 12.3% by physicians, 16.2% by general surgeons, 14.1% by other specialties and 15.3% diagnosed via the Bowel Screening Programme (BSP) TNM staging 113 patients (29.7%) had TxNxM1 and 267 with TxNxM0. From those with M0, 151 (56.6%) were N0M0 while the rest 43.4% had mets to at least one regional lymph node (N1 or greater) Surgical treatment 287 patients(75.5%) underwent surgical resection(including removal of liver mets) and 24.5% did not have a surgical procedure Chemotherapy 164 patients(43.2%) had chemotherapy (adjuvant or palliative), 138 did not require chemo post-operatively and 78 were not suitable for it. Recurrence From a total of 335 patients (45 patients were treated in different hospitals), 173 of them (51.6%) did not have any recurrence until June 2015 while the rest 48.4% had recurrence or died from the cancer. <h3>Conclusion</h3> Compared to the National UK data, this is a representative sample of new bowel cancer diagnosis in terms of demographics and anatomical site (55.7% male, 44.3% female, 95% 50 years old or more). Only exception is the higher number of descending and rectal tumours in Leighton Hospital. GPs continues to play an important role in diagnosis of bowel cancer but BSP has also improved the rate of diagnosis Regarding TNM staging, 30% of patients were diagnosed in advanced stage which is higher than the UK(10% diagnosed at stage 4) and creates questions as to how effectively people are referred for specialist review in Leighton Hospital. Finally, 76.7% of the patients survived one year after their diagnosis (75.7% in the UK) and 75.5% underwent major resection (62% in the UK) Overall, this study demonstrates that a district general hospital can provide a colorectal service comparative to national standards. <h3>Disclosure of Interest</h3> None Declared
Long Term Follow up Analysis Following Front Line Therapy with Dexamethasone or Dexamethasone Plus Rituximab in Adults with Primary Immune Thrombocytopenia.
Authors: Francesco Zaja, Michele Baccarani, Patrizio Mazza, Nicola Vianelli, Monica Bocchia, Marzia Defina, Luigi Gugliotta, Alessia Tienghi, Sergio Amadori, Selenia Campagna, Felicetto Ferrara, Mariacarla De Simone, Alfonso Zaccaria, Anna Lia Molinari, Emanuele Angelucci, Emilio Usala, Silvia Cantoni, Antonella Fornaro, Giuseppe Visani, Rita Rizzi, Valerio De Stefano, Francesco Casulli, Marta Battista, Miriam Isola, Franca Soldano, Renato Fanin
Journal: Blood (2009)
Cisplatin-Based Chemotherapy Is Associated with An Unacceptably High Incidence of Thromboembolic Events: A Large Retrospective Analysis.
Authors: Russell A. Moore, Nelly G. Adel, Manisha Bhutani, Nour Elise Tabbara, Heather Landau, Stephen D Nimer, Darren R. Feldman, Hani Hassoun
Journal: Blood (2009)
Guidelines for the Standardization of Acute Graft-Versus-Host Disease Clinical Data Collection: An International Consensus Report
Authors: Andrew C. Harris, Rachel Young, Steven M. Devine, William J Hogan, Francis Ayuk, Udomsak Bunworasate, Chantiya Chanswangphuwana, Yvonne A Efebera, Ernst Holler, Mark R Litzow, Rainer Ordemann, Muna Qayed, Anne S. Renteria, Ran Reshef, Matthias Wölfl, Yi-Bin Chen, Steven Goldstein, Madan H. Jagasia, Franco Locatelli, Stephan Mielke, David L Porter, Tal Schechter, Zhanna Shekhovtsova, James L.M. Ferrara, John E. Levine
Journal: Blood (2015)
Defining Primary Marrow Microenvironment-Induced Synthetic Lethality and Resistance for 2,684 Approved Drugs Across Molecularly Distinct Forms of Multiple Myeloma
Authors: Megan Murnane, Eugen Dhimolea, Ruojing Li, Megan A. Bariteau, Diamond D. Wheeler, Rosemary J. Akhurst, Aaron C. Logan, Pamela Munster, Arun Wiita, Thomas G. Martin, Jeffrey L. Wolf, Jun O. Liu, Constantine S. Mitsiades, Blake T. Aftab
Journal: Blood (2015)
A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma
Authors: Jacob M. Kaufman, Tadaaki Yamada, Kyungho Park, Cynthia D. Timmers, Joseph M. Amann, David P. Carbone
Journal: Cancer Research (2016)

Abstract LKB1 is a commonly mutated tumor suppressor in non–small cell lung cancer that exerts complex effects on signal transduction and transcriptional regulation. To better understand the downstream impact of loss of functional LKB1, we developed a transcriptional fingerprint assay representing this phenotype. This assay was predictive of LKB1 functional loss in cell lines and clinical specimens, even those without detected sequence alterations in the gene. In silico screening of drug sensitivity data identified putative LKB1-selective drug candidates, revealing novel associations not apparent from analysis of LKB1 mutations alone. Among the candidates, MEK inhibitors showed robust association with signature expression in both training and testing datasets independent of RAS/RAF mutations. This susceptibility phenotype is directly altered by RNA interference–mediated LKB1 knockdown or by LKB1 re-expression into mutant cell lines and is readily observed in vivo using a xenograft model. MEK sensitivity is dependent on LKB1-induced changes in AKT and FOXO3 activation, consistent with genomic and proteomic analyses of LKB1-deficient lung adenocarcinomas. Our findings implicate the MEK pathway as a potential therapeutic target for LKB1-deficient cancers and define a practical NanoString biomarker to identify functional LKB1 loss. Cancer Res; 77(1); 153–63. ©2016 AACR.
History and epidemics in modern Asia
Authors: Patou Masika Musumari, Teeranee Techasrivichien, S Pilar Suguimoto, Masako Ono-Kihara, Masahiro Kihara
Journal: The Lancet Infectious Diseases (2016)

Suddenly the corner of the world map occupied by Asia, formerly painted monochrome, is transformed into a multidimensional colour display with society, culture, economy, and politics as its axes. This display vividly shows how epidemics of infectious diseases, such as plague, malaria, and cholera, as well as the more recent severe acute respiratory syndrome, Nipah virus, and Zika virus outbreaks, contributed—or continue to contribute—to shaping the process of modernisation in Asia, especially east Asia.
Conserved Transcriptional Deregulation Underlies GFI1 and ELANE Mutant Neutropenia
Authors: H. Andre Olsson, Andrew Plassard, Phillip Dexheimer, James D. Phelan, Ari Melnick, Jun Xia, Daniel C. Link, Joseph Opferman, Bruce J Aronow, H. Leighton Grimes
Journal: Blood (2011)
Nilotinib (Tasigna®) and Chemotherapy for First-Line Treatment in Elderly Patients with De Novo Philadelphia Chromosome/BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL): A Trial of the European Working Group for Adult ALL (EWALL-PH-02)
Authors: Oliver G. Ottmann, Heike Pfeifer, Jean-Michel Cayuela, Karsten Spiekermann, Joachim Beck, Wolfram E Jung, Andreas Viardot, Schäfer-Eckart Kerstin, Albrecht Reichle, Sébastien Maury, Norbert Schmitz, Daniela Heidenreich, Jens Panse, Christian Junghanß, Emmanuel Raffoux, Felipe Suarez, Gäelle Guillerm, Magda Alexis, Severine Lissandre, Françoise Huguet, Françoise Isnard, Stephane Lepretre, Martine Escoffre-Barbe, Josep-Maria Ribera, Nicola Goekbuget, Herve Dombret, Dieter Hoelzer, Philippe Rousselot
Journal: Blood (2014)
Pre-Clinical and Interim Results of a Phase II Trial of Perifosine In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Authors: Daphne R. Friedman, Patricia H. Davis, Mark C. Lanasa, Joseph O. Moore, Jon P. Gockerman, Taylor Nelson, Karen M. Bond, Ning Jiang, Evan D. Davis, Sallie D. Allgood, Youwei Chen, Peter Sportelli, J. Brice Weinberg
Journal: Blood (2010)
Two Distinct Mechanisms Contribute to Granulomonocytic Hyperplasia in Chronic Myelomonocytic Leukemias (CMML)
Authors: Raphael Itzykson, Olivier Kosmider, Aline Renneville, Margot Morabito, Dorothee Buet, Claude Preudhomme, Céline Berthon, Lionel Ades, Pierre Fenaux, Uwe Platzbecker, Olivier Gagey, Philippe Rameau, Francois Delhommeau, Olivier A. Bernard, Michaela Fontenay, William Vainchenker, Nathalie Droin, Eric Solary
Journal: Blood (2012)
Impact of Occult Bone Marrow Involvement on Outcome in Diffuse Large B-Cell Lymphoma Treated with R-CHOP
Authors: Hiroshi Arima, Hayato Maruoka, Koji Nasu, Yuki Funayama, June Takeda, Nobuhiko Yamauchi, Kazunari Aoki, Aiko Kato, Yuichiro Ono, Seiji Nagano, Yoko Takiuchi, Sumie Tabata, Akiko Matsushita, Yukihiro Imai, Takayuki Takahashi, Takayuki Ishikawa
Journal: Blood (2011)
Plerixafor Single Agent for Autologous Stem Cells Mobilization and Collection in Adult Thalassemic Patients: Towards the Assessment of the Suitable Hematopoietic Stem Cell Source for Gene Therapy of Beta-Thalassemia.
Authors: Marta Claudia Frittoli, Bernhard Gentner, Maria Rosa Lidonnici, Annamaria Aprile, Laura Bellio, Salvatore Gattillo, Matilde Zambelli, Raffaella Milani, Elena Cassinerio, Laura Zanaboni, Silvano Rossini, Maria Domenica Cappellini, Fabio Ciceri, Giuliana Ferrari, Sarah Marktel
Journal: Blood (2012)
Flow Cytometry Detection of BCR-ABL Fusion Proteins in Leukemia Patients- An Indian Experience.
Authors: Soma Mukhopadhyay, Ujjal Kanti Roy, Ritwik Pandey, Pinaki Gupta, Jayasri Basak, Sanjay Sarkar, Ashis Mukhopadhyay, Haemato
Journal: Blood (2009)
AB1072 General Practitioner Perceptions of Methotrexate and anti-TNF Treatments: A Qualitative Study
Authors: E. Berthet, M. De Rosa, J. Lopez, P. Vorilhon, M. Soubrier, S. Mathieu
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The objective of rheumatic disease management is to achieve remission. Methotrexate (MTX) is the first-line treatment choice and tumor necrosis factor alpha antagonists (anti-TNFs) are used in case of MTX failure or intolerance. While these treatments are initially prescribed then renewed by rheumatologists, general practitioners (GPs) are often confronted with them during routine patient follow-up. <h3>Objectives</h3> We sought to study the perceptions of GPs from Auvergne (a region of France) regarding MTX and anti-TNFs treatments in common daily practice. <h3>Methods</h3> A qualitative study was carried out among 14 GPs following up patients receiving methotrexate and anti-TNFs. The semi-structured interviews were conducted between May and October, 2014. Thematic transversal analyses of the data were conducted by both the interviewer and an independent researcher. Each difference detected between them was discussed, then resolved by consensus. <h3>Results</h3> Of the 285 physicians who completed a preliminary questionnaire, 31 consented to participate in the qualitative. A total of 14 interviews, sufficient to obtain data saturation, <i>i.e.,</i> until no new data emerged, were conducted, lasting between 8 minutes and 1 hour, with a mean duration of 23 minutes 30 seconds. In total, 57% of the physicians interviewed were female and 42% of all practiced within 15km of a rheumatologist. The participating physicians were either young doctors (14%) or had over 20 years of experience (78%). Four principal themes were recognized in the analysis: the GP9s role with regard to the patients, their experience and difficulties concerning these treatments, their opinions of therapeutic education programs, as well as the need for improvements in clinical practices. The physician9s role consisted in renewing methotrexate prescription (10/14) and managing comorbidities <i>via</i> vaccination, for example (7/14). The GPs reported good tolerance (10/14) and efficacy (8/14) with the treatments. However, there was still concern over the immunosuppression and increased infection risk associated with these treatments, causing them to hesitate in using them. The difficulties especially concerned drug interactions and managing anti-TNF discontinuation in the event of infection (5/14), especially for rural-based practices with less easy access to specialists. All the physicians expressed a desire for a practical tool to be implemented aiding them to manage these treatments (10/14). <h3>Conclusions</h3> All the physicians reported difficulties in their daily management of these treatments. Close collaboration between GPs and specialists thus appears essential for this management. GP training is also to be encouraged. <h3>Disclosure of Interest</h3> None declared
Reversine: A Chemical Probe Providing Insight into Myeloma Biology and Potential Therapeutic Applications.
Authors: Douglas W. McMillin, D. Corey Geer, Joseph M. Negri, Nicholas Mitsiades, Teru Hideshima, Dharminder Chauhan, Yu-Tzu Tai, Nikhil C. Munshi, Paul G. Richardson, Kenneth C. Anderson, Constantine S. Mitsiades
Journal: Blood (2006)
Combined Use of Palifermin and Pegfilgrastim Significantly Reduces Toxicity of High-Dose Therapy and Autologous Blood Stem Cell Transplantation in Patients with Multiple Myeloma.
Authors: Guido Kobbe, Nadine Hieronimus, Thorsten Graef, Ingmar Bruns, Arcos Cibere, Fabian Zohren, Ulrich Steidl, Ulrich Germing, Rainer Haas, Roland Fenk
Journal: Blood (2006)
Exosomes Derived from AML/MDS Cells Is Involved in Stromal Dysfunction and Bone Marrow Failure
Authors: Hiroto Horiguchi, Masayoshi Kobune, Shohei Kikuchi, Wataru Jomen, Kazuyuki Murase, Soushi Ibata, Satoshi Iyama, Tsutomu Sato, Yusuke Kamihara, Koji Miyanishi, Yasushi Sato, Tsuyoshi Hayashi, Rishu Takimoto, Junji Kato
Journal: Blood (2014)
PWE-040 Natural History of Cirrhosis in A Cohort of Patients Undergoing Structured Surveillance for Hepatocellular Carcinoma: Results from The Aberdeen Surveillance Cohort
Authors: S Lalwani, A Mukhopadhya, A Fraser, GL Hold, L Bailey, B Vijayan, S English, L Mcleman
Journal: Gut (2016)

<h3>Introduction</h3> Cirrhosis is the end-stage of chronic liver disease due to a variety of different aetiologies with the natural history of this condition characterised by a variable asymptomatic phase of compensation followed by a rapid ‘decompensated’ phase marked by ascites, jaundice, variceal bleeding, encephalopathy and development of hepatocellular carcinoma (HCC). The cornerstone of management for cirrhotic subjects includes 6 monthly surveillance to detect development of HCC. Aberdeen Royal Infirmary is one of the few centres in the UK to have a structured HCC screening program where patients are followed up in a nurse led clinic. The aim of this study was to determine rates of decompensation and development of HCC in a cohort of cirrhotic patients undergoing structured surveillance. <h3>Methods</h3> The electronic records of 231 patients who were initiated on surveillance between the years 2010–2015 were reviewed. Only patients who attended the clinic on at least 2 occasions were included. Those with a prior history of HCC or had an HCC discovered at their first ultrasound were excluded. Primary end-points studied were the time to develop ascites, variceal haemorrhage, hepatic encephalopathy, jaundice, HCC and mortality. Data analyses were conducted using SPSS version 23. Statistical methods used include Cox regression and Kaplan Meier survival analyses. <h3>Results</h3> The 231 patients included in the study were mostly male (61.5%) with alcohol being the predominant aetiological factor (33.3%). The mean age at entry into the cohort was 58.1± 11.2 years, with a mean MELD of 8.6±2.9 and UKELD of 48.2± 3.1. The median follow-up duration was 26 months (range 6–60) giving a total cohort follow up of 522 patient years. Most patients had compensated and Childs-Pugh A cirrhosis at the time of entry (62.8% and 60.2% respectively). Of the 145 patients with compensated cirrhosis at entry, 26 (19.9%) developed jaundice or other signs of decompensation during follow up. Mean time to first decompensation episode was 49 (95% CI; 45–52) months, giving a rate of 8.7 /100 patient years. During follow-up, 7 patients developed HCC giving a detection rate of 1.36/100 patient-years. Mean age at detection of HCC was 71.6 ± 7.3 years. Mortality rate in the entire cohort was 3.6/100 patient years. <h3>Conclusion</h3> The results from our surveillance cohort outline the natural history of a large group of cirrhotic patients systematically followed up in a structured nurse-led clinic. The rates of decompensation and HCC highlight the importance of pursuing the strategy of active surveillance. <h3>Disclosure of Interest</h3> None Declared
Lycorine Downregulates HMGB1 to Inhibit Autophagy and Enhances Bortezomib Activity in Multiple Myeloma
Authors: Mridul Roy, Long Liang, Xiaojuan Xiao, Yuanliang Peng, Yuhao Luo, Weihua Zhou, Ji Zhang, Lugui Qiu, Shuaishuai Zhang, Feng Liu, Mao Ye, Wen Zhou, Jing Liu
Journal: Theranostics (2016)

Multiple myeloma (MM) is largely incurable and drug-resistant.Novel therapeutic approaches such as inhibiting autophagy or rational drug combinations are aimed to overcome this issue.In this study, we found that lycorine exhibits a promising anti-proliferative activity against MM in vitro and in vivo by inhibiting autophagy.We identified High mobility group box 1 (HMGB1), an important regulator of autophagy, as the most aberrantly expressed protein after lycorine treatment and as a critical mediator of lycorine activity.Gene expression profiling (GEP) analysis showed that higher expression of HMGB1 is linked with the poor prognosis of MM.This correlation was further confirmed in human bone marrow CD138 + primary myeloma cells and MM cell lines.Mechanistically, proteasomal degradation of HMGB1 by lycorine inhibits the activation of MEK-ERK thereby decreases phosphorylation of Bcl-2 resulting in constitutive association of Bcl-2 with Beclin-1.In addition, we observed higher HMGB1 expression in bortezomib resistant cells and the combination of bortezomib plus lycorine was highly efficient in vitro and in vivo myeloma models as well as in re-sensitizing resistant cells to bortezomib.These observations indicate lycorine as an effective autophagy inhibitor and reveal that lycorine alone or in combination with bortezomib is a potential therapeutic strategy.
Human Immune Responses to AAV-2 Capsid May Limit Duration of Expression in Liver-Directed Gene Transfer in Humans with Hemophilia B.
Authors: Katherine High, Michael Tigges, Catherine Manno, Denise Sabatino, Valder Arruda, Roland Herzog, Pradip Rustagi, John Rasko, Jurg Sommer, Kristen Jaworski, Margaret Ragni, Bertil Glader, Ruth Lessard, Alvin Luk, Linda Couto, Haiyan Jiang, Glenn Pierce, Mark Kay
Journal: Blood (2004)
Preliminary Results from the Surveillance, Epidemiology &amp; Risk Factors for TTP (SERF-TTP) Group: A Prospective Case-Control Study of Idiopathic TTP.
Authors: Anaadriana Zakarija, H.C. Kwaan, Nicholas Bandarenko, Dilip Pandey, Amul Tevar, John Cursio, Charles Buffie, Thomas Ortel, Jeffrey Winters, Joseph Kiss, Ravindra Sarode, Charles Bennett
Journal: Blood (2006)
Methylation of Specific Microrna Genes In MLL-Rearranged Infant Acute Lymphoblastic Leukemia: - Major Matters at a Micro Scale -
Authors: Dominique JPM Stumpel, Diana Schotte, Ellen AM Lange-Turenhout, Pauline Schneider, Lidija Seslija, Renee X de Menezes, Victor E Marquez, Rob Pieters, Monique L. Den Boer, Ronald Stam
Journal: Blood (2010)
PWE-051 Small Bowel Adenocarcinoma: Single Centre Experience Over 6 Years
Authors: F Moroni, G Murray, G Bain
Journal: Gut (2016)

<h3>Introduction</h3> Small bowel (SB) cancer is a rare condition (&lt;5% of all gastrointestinal cancers). Small bowel adenocarcinoma (SBA) accounts for 40% of SB cancers. Incidence is rising, with an estimated 3600 cases per year in Europe, led by an increasing number of sporadic duodenal cases.<sup>1,2</sup> Besides known predisposing conditions (i.e. Coeliac, Crohn’s and familial diseases), alcohol consumption and smoking have been identified as environmental risk factors for SBA.<sup>3</sup> We reviewed cases of SBA in Aberdeen Royal Infirmary from 2010 to 2015 and compared with the available literature. <h3>Methods</h3> We obtained all histology confirming SBA over the past 6 years from our Pathology Department. Patient case notes and electronic records were reviewed and relevant data as per literature review collected. <h3>Results</h3> 28 cases of SBA were confirmed during 6 years: 17 male and 11 female (1.5:1 ratio). Mean age at diagnosis was 65 (46–82).19 cases (68%) from duodenum, 8 (28%) jejunum and 1 ileum. Majority were sporadic (22, 79%), 3 had Crohn’s Disease, 2 genetic conditions (FAP and HNPCC) and 1 Coeliac disease.16 cases were diagnosed via radiology (57%), 10 (36%) via endoscopy and 2 incidentally at surgery. The commonest presentation was bowel obstruction (11, 39%), followed by melaena (6, 21%) and jaundice (3, 11%). Disease was advanced at time of diagnosis: 19 (68%) had at least T4N1 disease or metastasis. 17 patients (61%) died during this period with 76% mortality at 1 year. Average survival was 216 days.We found positive correlation between alcohol consumption and both staging and mortality in sporadic cancers (Pearson 0.8). The 3 youngest patients had Crohn’s disease for &gt;15 years with small bowel involvement, 2 had previous surgery and had been on Azathioprine for over 10 years, in 1 case this was discontinued for 12 years at time of cancer diagnosis. 1 Coeliac disease patient was diagnosed in his 7 th decade and developed duodenal cancer 6 years later. <h3>Conclusion</h3> Our population findings are comparable to current literature. We confirm a high number of sporadic duodenal adenocarcinomas. Late presentation with bowel obstruction and an advanced stage of disease results in a high mortality, We demonstrated correlation between alcohol consumption and both mortality and disease severity. Smoking did not appear to be an environmental risk factor in our population. This may be due to our small sample size. Multi-centre collaboration would allow formation of larger registries and facilitate research in this area. <h3>References</h3> 1 Shenoy S, <i>et al. J Gastrointest Cancer</i>. 2014 Dec;<b>45</b>(4):421–30. 2 Chow JS, <i>et al. International Journal of Epidemiology</i> 1996;<b>25</b>:722–8. 3 M. Bennett, <i>et al. Cancer Epidemiol</i> 2015 Jun;<b>39</b>(3):265–73. <h3>Disclosure of Interest</h3> None Declared
Outcome of Patients (pts) with Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) Post Decitabine Failure.
Authors: Elias Jabbour, Guillermo Garcia-Manero, Jianqin Shan, Susan O’Brien, Jorge Cortes, Farhad Ravandi, Jean-Pierre J Issa, Hagop M Kantarjian
Journal: Blood (2008)
Are Outcomes After Myeloablative Conditioning Regimen in Double Cord Blood Transplantation (UCBT) Better Than Single UCBT for Adults with Acute Leukemia in Remission?.
Authors: Annalisa Ruggeri, Henrique Bittencourt, Guillermo Sanz, Alessandro Rambaldi, Ibrahim Yakoub-Agha, Josep-Maria Ribera, William Arcese, Lionel Mannone, J. Sierra, Carlos Solano, Samir Kanaan Nabhan, Luciana Tucunduva, Fernanda Volt, Chantal Kenzey, Eliane Gluckman, Myriam Labopin, Vanderson Rocha
Journal: Blood (2012)
Prophylactic and Preemptive Anti-Fungal Therapy after Cord Blood Transplantation: A Retrospective Analyses of 188 Adult Patients.
Authors: Yoshiko Matsuhashi, Shinsuke Takagi, Hisashi Yamamoto, Daisuke Kato, Naofumi Matsuno, Sachiko Seo, Naoyuki Uchida, Kazuhiro Masuoka, Atsushi Wake, Shigesaburo Miyakoshi, Akiko Yoneyama, Shuichi Taniguchi
Journal: Blood (2006)